Kornimate/medical-research-clean huggingface dataset:
improving infant hydrocephalus outcomes in uganda

Conditions: Hydrocephalus

Summary: neonatal postinfectious hydrocephalus (pih) is a major public health problem in east africa.the standard treatment has long been placement of a ventriculoperitoneal shunt (vps) but these devices require life-long maintenance and nearly all fail multiple times. endoscopic third ventriculostomy (etv) with choroid plexus cauterization (etv/cpc) is an alternate treatment to give patients a shunt-free life. in this study, the investigators aim to optimize the metrics of evaluation as quantitative prognostic indicators of treatment response and long term outcomes.


Eligibility criteria:
inclusion criteria: * infants less than 180 days (six months) old * symptomatic hydrocephalus characterized by abnormal rate of head growth, full anterior fontanel, ventriculomegaly * a parent or a guardian qualified by ugandan law to give informed consent * patients from eastern, central and northern districts of uganda, and in geographic proximity to cure hospital will be eligible exclusion criteria: * age greater than six months * no evidence of progressive hydrocephalus * patients outside of the districts specified in the inclusion criteria

Keywords: hydrocephalus
sleeper's and adduction stretch to increase shoulder rom

Conditions: Stiffness of Shoulder, Not Elsewhere Classified

Summary: the study aimed to compare the efficacy of modified sleeper stretch and modified cross-body adduction stretch in improving shoulder internal rotation range of motion and upper limb function. thirty male lawn tennis players aged between 20 to 35, with more than 150 glenohumeral internal rotation deficiency (gird) on the dominant shoulder (compared to the nondominant side) participate in the study and divided into two groups (a and b). group a received a modified sleeper stretch and group b received a modified cross-body adduction stretch for four weeks, five times per week. the outcome measures were the internal rotation range of motion measured by a universal goniometer and upper limb functions measured by the disability of the arm, shoulder, and hand (dash) scale.


Eligibility criteria:
inclusion criteria: * lawn tennis players * male * more than 15 degree glenohumeral internal rotation deficiency exclusion criteria: * systemic or metabolic disorders * a positive test for labral lesions or rotator cuff tears * a history of recent fracture * a history of orthopaedic surgery in the upper limbs or cervical region

Keywords: sleeper stretch cross-body stretch range of motion shoulder tennis players
a dose-escalation study to evaluate the safety, tolerability and pharmacokinetic of lpm3770164 in healthy subjects

Conditions: Huntington Disease; Tardive Dyskinesia

Summary: this is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of lpm3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for subsequent clinical trials.


Eligibility criteria:
inclusion criteria: 1. subject who voluntarily participate and sign the informed consent form; 2. healthy male/female volunteers aged 18 to 45 years; 3. body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and body mass index (bmi) 18.5 \~ 28.0 kg/m2, inclusive; 4. able to comply with the lifestyle restrictions. exclusion criteria: 1. subject has a history of allergy to any component of the investigational drug or similar drugs, or allergic constitution; 2. subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results; 3. any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects;. 4. subject has a history of self-mutilation; or at risk of suicide; 5. subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial; 6. subject has abnormal vital signs, laboratory abnormalities, and ecgs; 7. subject has used any of over-the-counter products within 14 days or prescription medications within 28 days prior to dosing; 8. subject positive for hepatitis b surface antigen (hbsag), hepatitis c antibody (hcv-ab), hiv antibody (hiv-ab), or syphilis seroreactivity (trust); 9. subject has a history of alcohol abuse within 1 year or positive alcohol breath test results; 10. subject has a history of substance abuse or a positive urine drug screen; 11. subject who has daily smoking of ≥ 5 cigarettes; 12. subject who has consumption of xanthine-rich foods or beverages (such as tea, coffee, cola, or chocolate) within 3 days prior to administration; 13. subject who has consumption of food or beverages containing grapefruit within 7 days prior to administration; 14. subject who has participated in other clinical trials within 3 months before administration; 15. subject has used blood products or being blood donor or blood loss; 16. pregnant, lactating women, or positive pregnancy test; 17. subject who refusal to contraception, or plan to donate sperm or ovums; 18. other conditions which would make participation in the study unsuitable.
impact of influenza vaccination in pregnancy video education

Conditions: Influenza

Summary: we evaluated the impact of viewing an educational video about influenza vaccination in pregnancy just prior to a routine prenatal visit on vaccination health beliefs and vaccination rate. we hypothesized that the video would positively impact both vaccination health beliefs and vaccination rate compared to a control video.

we studied the impact of influenza in pregnancy video education that was developed by the cdc and currently available to the public on the internet. we looked to see if viewing the video just prior to a routine scheduled prenatal visit could positively influence health beliefs regarding vaccination and improve the rate of vaccination that day. patients were randomized to view the intervention video or a control video of similar length about hand washing. pre visit and post visit questionnaires were given about vaccination health beliefs. we also asked if the shot had been recommended by the physician. one month after the visit, we used a structured phone interview to gather additional information regarding why participants who had not been vaccinated made that choice.

Eligibility criteria:
inclusion criteria: * pregnant * english as primary language * scheduled for a routine prenatal visit * no documented influenza vaccination 2013-2014 exclusion criteria: * cleveland clinic employee * high risk pregnancy * allergy to eggs * allergy to influenza vaccination

Keywords: pregnancy vaccination influenza education
endoscopic ultrasound plus submucosal injection for early esophageal cancer

Conditions: Esophageal Cancer

Summary: preoperative accurately staging t1a or t1b in early esophageal cancer is vital for the choices of treatment. at present, the main diagnostic method for early esophageal cancer is endoscopic ultrasound (eus). however, the accuracy of eus alone is poor. thus, it is necessary to improve endoscopic ultrasound examination methods. this project is concerning on the efficacy of eus combining with submucosal injection of saline for staging t1a and t1b-esophageal cancer. patients and methods: 80 cases of pathological confirmed early esophageal cancer were randomly divided into two groups: endoscopic ultrasonography group (eus group) and eus combining with submucosal injecting saline group (eus+sis group). all the cases will be performance by endoscopic or surgical resection; postoperative pathologic diagnosis will be obtained involving echo, depth, margin and other features. the eus results of two groups of patients will be compared with pathologic results. from comparison, the efficacy and accuracy of eus+sis for staging t1a and t1b in esophageal cancer patients will be validated. through this study, the investigators may develop a routine diagnostic and accurately staging method for early esophageal cancer patients.

someone whom may concern our ipd are available to the pi, jian-jun li m.d. or at lijj@sysucc.org.cn

Eligibility criteria:
inclusion criteria: * age 18-65 years old, no gender limited; * patients with esophageal squamous cell carcinoma who be confirmed by ordinary endoscopy and pathologic biopsy; * patients who agree to accept endoscopic resection or surgical excision of the lesion in esophagus; * patients with normal cardio-pulmonary function and normal coagulative function,are predicted to be tolerated anesthesia and surgery; * patients who understand test purpose, volunteer to join these study and sign the consent inform. exclusion criteria: * patients with stages of t2, t3, or t4 displayed by eus; * patients who can't tolerate endoscopy and surgical treatment for various reasons; * patients who have distant metastasis, or multiple source of malignant tumors; * patients with blood coagulative disorder; * patients don't accept the endoscopic examination or surgical treatment; * patients with poor compliancy.

Keywords: esophageal cancer early cancer ultrasonography (eus) stage
fsh in gnrh-antagonist controlled ovarian hyperstimulation cycles (fast)

Conditions: Infertility

Summary: the purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety of two different subcutaneous fsh preparations (fostimon versus gonal-f) for controlled ovarian hyperstimulation in a gnrh-antagonist cycle.


Eligibility criteria:
inclusion criteria: * age: 18-38 years old; * bmi: 18-28 kg/m2; * less than 3 previously completed ivf cycles; * basal fsh \<10 iu/l and e2 \<80 pg/ml; * tsh \< 2.5 miu/l * \>10 and \<30 antral follicles 2-10 mm in size for both ovaries combined * amh: \>1 ng/ml (7.15 pmol/l) and \<5.6 ng/ml (40.0 pmol/l) * presence and adequate visualization of both ovaries; * within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through transvaginal ultrasound, hysterosalpingogram, sonohysterogram or hysteroscopic examination; exclusion criteria: * primary ovarian failure or women known as poor responders; * pco and pcos; * severe ohss in a previous coh cycle; * uterine malformation that may impair the possibility to get pregnant; * ovarian cysts \>10 mm; * hydrosalpinx that have not been surgically removed or ligated; * endometriosis stage 3 or 4; * oocyte donation; * severe male factor; * pathologies associated with any contraindication of being pregnant; * history of recurrent miscarriage (more than 3 previous miscarriages); * hypersensitivity to the study medication; * abnormal bleeding of undetermined origin; * uncontrolled thyroid or adrenal dysfunction; * neoplasias; * severe impairment of renal and/or hepatic function.

Keywords: in vitro fertilization (ivf) assisted reproduction technologies (art) gnrh-antagonist follicle stimulating hormone (fsh)
enabling microbiomics- driven personalized nutrition

Conditions: Inflammatory Bowel Disease (IBD); Irritable Bowel Syndrome (IBS); Celiac Disease; Diarrhea; Constipation; Microbiome; Crohn's Disease; UC - Ulcerative Colitis; Microscopic Colitis; Functional Dyspepsia

Summary: the goal of this observational research study is to determine how diet contributes to various gastrointestinal related conditions. the main question investigators aim to answer is: are host genetics, diet, and microbiome all important determinants of gi disorders, and how their relative contribution varies among individuals and populations.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * gastrointestinal patients with or without genomic sequencing results available for the following cohorts: * inflammatory bowel disease (ibd) * irritable bowel syndrome (ibs) * crohn's disease * celiac disease * diarrhea * constipation * healthy age and sex matched controls with or without genomic sequencing results available o control is defined as patients without gastrointestinal disease or no symptoms at time of sampling * able to provide written, informed consent * participant has a smartphone device with access to internet connection exclusion criteria: * patients with cognitive impairment * active use of antibiotics at the time of stool collection

Keywords: gi disorders microbiomics diet microbiome nutrition gi function
obinutuzumab in chinese real-world patients with inhl

Conditions: Lymphomas Non-Hodgkin's B-Cell

Summary: this study aims to assess the clinical efficacy and safety of obinutuzumab in chinese patients with indolent non-hodgkin b-cell lymphoma (predominantly follicular lymphoma and marginal zone lymphoma) in a real-world setting.

this study was a prospective, multicenter, non-interventional, real-world study. the study will be divided into two cohorts: cohort 1 is the younger cohort (aged ≥ 18 and \< 60 years at the start of treatment); cohort 2 is the older cohort (aged ≥ 60 years at the start of treatment). patients in this study will receive obinutuzumab-contained regimens according to the investigators' clinical opinion.

Eligibility criteria:
inclusion criteria: * age: age ≥ 18 years at the start of treatment; * be diagnosed with grade 1-3a follicular lymphoma, marginal zone lymphoma; * previously untreated or relapsed or refractory patients; * patients who started treatment with otuzumab between june 2021 and april 2023. exclusion criteria: * patients currently participating or planning to participate in any interventional clinical trial; * patients who, in the opinion of the investigator, are discomfort for any other reason to participate in this study.
dose effects of hormone therapy (two doses of estradiol associated to progesterone) on inflammatory markers

Conditions: Healthy Symptomatic Menopausal Women

Summary: primary purpose : effects of two doses of hormone therapy on hscrp. the effects of hormone replacement therapy on inflammatory markers are dose-dependent.

pro-inflammatory study of the effects in short term of two difference doses of 17beta-estradiol at the menopause woman

Eligibility criteria:
inclusion criteria: * symptomatic menopausal women : \>=50 years and amenorrhea \>=1 year or \ =1 year and plasmatic fsh \>= 30 ui/l * normal mammography in the last 2 years before inclusion * normal cervical smear in the last 2 years before inclusion * written consent for participation in the study exclusion criteria: * unconfirmed menopause with amenorrhoea of less than year * oestrogen-progesterone treatment anterior in 3 months previous the inclusion * recently a viral infection or bacteriologic(at least of 2 weeks) * dental infection * inflammatory pathology chronicles * antecedent of pathology cancerous with or no a sly hemopathy * addiction to smoking of more than 20 cigarettes a day or an alcoholic consumption furthermore of 4 glasses a day * taken concomitant of one of the treatments forbidden:statine, vitamin b6 or b12, folates, antiinflammatory, anti aggregant plaquettes, dhea, phytoestrogens * refusal to sign the assent informed * not membership in a regime about social security

Keywords: hormone menopause inflammation dose effects apoptosis
acute effects of whole-body vibration training in hypoxia and normoxia in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (me) is a degenerative, inflammatory and autoimmune demyelinating disease of the central nervous system, characterized by demyelination due to inflammation and degeneration of the myelin sheaths enveloping nerves of the eye, periventricular grey matter, brain, spinal cord and brainstem. the symptoms associated with ms include symptomatic fatigue, muscle weakness, ataxia, mobility and balance problems or cognitive problems. moderate intensity strength training has been shown to improve strength and mobility in persons with ms. it was suggested that whole-body vibration training (wbvt) is effective to improve muscle strength, such as resistance training, resulting from both neural and structural adaptations. on the other hand, traditional strength training in hypoxia has garnered much attention. this method has shown improvements in isometric strength and increases in muscle size.

* crossover. * 13 patients with multiple sclerosis were recruited. * patients performed two sessions: whole-body vibration training in normoxia condition and whole-body vibration in hypoxia condition.

Eligibility criteria:
inclusion criteria: * mild or moderate disability with clinical mild spastic-ataxic gait disorder. * stable phase of the disease. exclusion criteria: * expanded disability status scale (edss) \< 6. * relapsing disease within the preceding 12 months. * corticosteroid treatment within the last months before study inclusion.

Keywords: neuromuscular disease whole-body vibration hypoxia strength
mini-sized mce for detection of small bowel in children under the age of 10 years

Conditions: Small Bowel Disease

Summary: in this prospective randomized controlled trial, pediatric volunteers were enrolled and randomly underwent mini-sized mce and normal-sized ce to compare the success rate of self-swallowing between mini-sized mce and normal-sized ce during gastrointestinal examination.

magnetic controlled capsule endoscopy (mce) is comparable to traditional gastroscopy (egd) in the diagnosis of gastric diseases, and has been widely used in clinical practice. however, there are still some limitations in the application of mce in digestive tract examination. due to the large size of capsules at present, some patients have difficulty swallowing capsules during capsule swallowing, which leads to the failure of examination, and the proportion is higher in children patients. therefore, in order to further improve the patient's comfort in swallowing capsules, our team developed a small mce with a smaller size combined with innovation, which is 0.6 times of the conventional mce in terms of volume and weight. this study aims to clarify the application efficacy of mini-mce in gastrointestinal examination of adults and children through a multicenter clinical study comparing conventional capsule endoscopy with mini-magnetic-controlled capsule endoscopy. in order to ensure the efficacy of the capsule in the examination of digestive tract mucosa, and improve the ease of swallowing in children.

Eligibility criteria:
inclusion criteria: * patients and their legal guardians agreed to participate in the study and signed informed consent; * 2 years ≤ age \< 10 years; * pediatric patients with suspected small bowel disease who are scheduled for small bowel capsule endoscopy exclusion criteria: * intestinal obstruction, stenosis, or fistula is known or suspected; * dysphagia or gastric emptying dysfunction; * severe asthma, dysphagia or gastroparesis and other emptying disorders; * known or suspected possibility of major bleeding from active digestive tract; * the presence of a pacemaker in the body, except where the pacemaker is a new mri-compatible product; * implanted cochlear implants, magnetic metal drug infusion pumps, nerve stimulators and other electronic devices, as well as magnetic metal foreign bodies; * those who plan to undergo magnetic resonance imaging (mri) examination before capsule endoscopy discharge; * previous history of abdominal surgery affecting the normal structure of the digestive tract; * patients with mental illness; * allergic to macromolecular materials such as dimethyl silicone oil; * refuse to use electronic gastroscopy to deliver the capsule to the duodenum if the capsule cannot be swallowed by itself; * contraindications of intravenous anesthesia; * patients who have participated in or are participating in other clinical trials within three months; * any other factors considered by the investigator to be inappropriate for enrollment or to affect the participant's participation in the study.

Keywords: children small bowel disease capsule endoscopy
efficacy and safety of basic triple therapy including ilaprazole on the first line eradication treatment of h.pylori

Conditions: Helicobacter Infections

Summary: this study compared efficacy and safety of basic triple therapy including ilaprazole 10mg, levofloxacin 500mg and amoxicillin 1000mg bid for 10 days on the first line eradication treatment of h.pylori

this study compared efficacy and safety of basic triple therapy including noltec(ilaprazole) 10mg, cravit(levofloxacin) 500mg and chongkundang amoxicillin cap(amoxicillin) 1000mg bid on the first line eradication treatment of h.pylori. participants are defined as persons who have endoscopically confirmed on gastric or duodenal ulcer(including scar stage) and gastritis confirmed to be h.pylori positive patients in the biopsy and ubt test. for 10 days, participants treated as basic triple therapy including noltec(ilaprazole) 10mg, cravit(levofloxacin) 500mg and chongkundang amoxicillin cap(amoxicillin) 1000mg bid. after treatment, the healing rate was evaluated in the ubt test and biopsy at 49±5days from the first day dosing.

Eligibility criteria:
inclusion criteria: * subject must have endoscopically confirmed on gastric, duodenal ulcer(including scar) or gastritis confirmed to be h.pylori positive patients in the biopsy and ubt test. * subject who fully understands conditions of clinical trial. * subject who agrees to participate and spontaneously sign the icf exclusion criteria: * known hypersensitivity to any component of ilaprazole, amoxicillin and levofloxacin * subjects who are taking contraindicated medications for experimental and concomitant drug. * patients with abnormal levels in the laboratory tests * total bilirubin, creatinine\> 1.5 times upper limit of normal * ast, alt, alkaline phosphatase, bun\> 2 times upper limit of normal * administrated of ppi, antibiotic medication within 4 weeks prior to commencement of the study. * pregnant and/or lactating women * reproductive aged women not using contraception * uncontrolled diabetics * uncontrolled hypertension * uncontrolled liver dysfunction * alcoholics * subjects with a history of digestive malignancy within 5 years * subjects with a history of gastrectomy or esophagectomy * subjects with hereditary diseases such as galactose intolerance, lapp lactose deficiency, glucose-galactose malabsorption. * subjects participating in a clinical trial before another trial wihin 30 days * inconsistence judged subject by researcher

Keywords: helicobacter pylori ilaprazole eradication triple therapy